StreetInsider.com News Articles

Form 3 Adlai Nortye Ltd. For: Mar 18 Filed by: Birgerson Lars Erik

Tue, 04 Aug 2026 10:58:00 -0400

si-local-file:///var/storage/secattach/20260804/26863821.html

Form 3 Adlai Nortye Ltd. For: Mar 18 Filed by: Birgerson Lars Erik

Tue, 04 Aug 2026 10:58:00 -0400

si-local-file:///var/storage/secattach/20260804/26863821.html

Form 6-K Adlai Nortye Ltd. For: Aug 03

Mon, 03 Aug 2026 08:00:00 -0400

si-local-file:///var/storage/secattach/20260803/26854169.html

Form 6-K Adlai Nortye Ltd. For: Aug 03

Mon, 03 Aug 2026 08:00:00 -0400

si-local-file:///var/storage/secattach/20260803/26854169.html

Adlai Nortye clears regulatory hurdle for AN4035 cancer drug trial

Mon, 03 Aug 2026 07:02:41 -0400

Adlai Nortye Ltd. (NASDAQ: ANL) announced it has submitted a Clinical Trial Notification to Australia's Therapeutic Goods Administration and received approval from the Human Research Ethics Committee to begin a phase I clinical trial of AN4035, an antibody drug conjugate targeting CEACAM5-enriched, RAS-addicted solid tumors.

AN4035 is designed to deliver a pan-RAS(ON) inhibitor payload to tumor cells by targeting the CEACAM5 antigen, which is overexpressed in colorectal, pancreatic, and lung cancers. The drug is the first candidate from the company's RASiCA™ platform.

The phase I trial will assess safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary efficacy of AN4035 as a monotherapy and in

Adlai Nortye clears regulatory hurdle for AN4035 cancer drug trial

Mon, 03 Aug 2026 07:02:41 -0400

The phase I trial will assess safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary efficacy of AN4035 as a monotherapy and in

Adlai Nortye Announces Clinical Trial Notification Submission and HREC Approval for the Phase I Clinical Trial of Pan-RAS(ON) Inhibitor ADC AN4035 in Australia

Mon, 03 Aug 2026 07:00:00 -0400

First-in-class pan-RAS(ON) ADC is cleared for clinical development

Designed to selectively deliver pan-RAS(ON) inhibition to tumors while minimizing systemic toxicity.

IND submissions to U.S. FDA and China NMPA are in process

SINGAPORE and NORTH BRUNSWICK, N.J., Aug. 03, 2026 (GLOBE NEWSWIRE) -- Adlai Nortye Ltd. (NASDAQ: ANL) (“Adlai Nortye” or the “Company”), a clinical-stage biotechnology company focused on the development of innovative cancer therapies, today announced that it has submitted a Clinical Trial Notification (CTN) to Australia's Therapeutic Goods Administration (TGA) and received approval from the Human Research Ethics Committee (HREC) to

Adlai Nortye Announces Clinical Trial Notification Submission and HREC Approval for the Phase I Clinical Trial of Pan-RAS(ON) Inhibitor ADC AN4035 in Australia

Mon, 03 Aug 2026 07:00:00 -0400

First-in-class pan-RAS(ON) ADC is cleared for clinical development

Designed to selectively deliver pan-RAS(ON) inhibition to tumors while minimizing systemic toxicity.

IND submissions to U.S. FDA and China NMPA are in process

Adlai Nortye Announces Clinical Trial Notification Submission and HREC Approval for the Phase I Clinical Trial of Pan-RAS(ON) Inhibitor ADC AN4035 in Australia

Mon, 03 Aug 2026 07:00:00 -0400

First-in-class pan-RAS(ON) ADC is cleared for clinical development

Designed to selectively deliver pan-RAS(ON) inhibition to tumors while minimizing systemic toxicity.

IND submissions to U.S. FDA and China NMPA are in process

Adlai Nortye Announces Clinical Trial Notification Submission and HREC Approval for the Phase I Clinical Trial of Pan-RAS(ON) Inhibitor ADC AN4035 in Australia

Mon, 03 Aug 2026 07:00:00 -0400

First-in-class pan-RAS(ON) ADC is cleared for clinical development

Designed to selectively deliver pan-RAS(ON) inhibition to tumors while minimizing systemic toxicity.

IND submissions to U.S. FDA and China NMPA are in process

Form 424B7 Adlai Nortye Ltd.

Mon, 20 Jul 2026 09:23:00 -0400

si-local-file:///var/storage/secattach/20260720/26787985.html

Form 424B7 Adlai Nortye Ltd.

Mon, 20 Jul 2026 09:23:00 -0400

si-local-file:///var/storage/secattach/20260720/26787985.html

Form 6-K Adlai Nortye Ltd. For: Jul 16

Fri, 17 Jul 2026 06:02:00 -0400

si-local-file:///var/storage/secattach/20260717/26781469.html

Form 6-K Adlai Nortye Ltd. For: Jul 16

Fri, 17 Jul 2026 06:02:00 -0400

si-local-file:///var/storage/secattach/20260717/26781469.html

Adlai Nortye doses first patient in weekly arm of AN9025 trial

Thu, 16 Jul 2026 07:00:24 -0400

Adlai Nortye Ltd. (NASDAQ: ANL) announced that the first patient has been dosed in the United States in the intermittent weekly dosing arm of its ongoing Phase 1 clinical trial of AN9025, a pan-RAS(ON) inhibitor, according to a press release.

The Phase 1 study is a first-in-human, multicenter, open-label trial evaluating the safety, tolerability, pharmacokinetics, and anti-tumor activity of AN9025 in patients with advanced or metastatic solid tumors harboring RAS mutations. Both the daily dosing and weekly dosing arms are now enrolling.

The trial is being conducted by Adlai Nortye in collaboration with Jiangsu Aosaikang Pharmaceutical Co. Ltd. under a license agreement.

Adlai Nortye Announces First Patient Dosed in Intermittent Weekly Dosing Arm of Global Phase 1 Trial of Pan-RAS(ON) Inhibitor AN9025

Thu, 16 Jul 2026 07:00:00 -0400

First patient dosed in intermittent QW dosing arm with AN9025

Intermittent dosing offers a differentiated approach in the pan-RAS(ON) inhibitor space and may widen the therapeutic window based on preclinical data

Both QD and QW arms are now enrolling

SINGAPORE and NORTH BRUNSWICK, N.J., July 16, 2026 (GLOBE NEWSWIRE) -- Adlai Nortye Ltd. (NASDAQ: ANL) (“Adlai Nortye” or the “Company”), a clinical-stage biotechnology company focused on the development of innovative cancer therapies, today announced that the first patient has been dosed in the United States in the intermittent weekly dosing (QW) arm

Adlai Nortye Announces First Patient Dosed in Intermittent Weekly Dosing Arm of Global Phase 1 Trial of Pan-RAS(ON) Inhibitor AN9025

Thu, 16 Jul 2026 07:00:00 -0400

First patient dosed in intermittent QW dosing arm with AN9025

Intermittent dosing offers a differentiated approach in the pan-RAS(ON) inhibitor space and may widen the therapeutic window based on preclinical data

Both QD and QW arms are now enrolling

Adlai Nortye Announces First Patient Dosed in Intermittent Weekly Dosing Arm of Global Phase 1 Trial of Pan-RAS(ON) Inhibitor AN9025

Thu, 16 Jul 2026 07:00:00 -0400

First patient dosed in intermittent QW dosing arm with AN9025

Intermittent dosing offers a differentiated approach in the pan-RAS(ON) inhibitor space and may widen the therapeutic window based on preclinical data

Both QD and QW arms are now enrolling

Adlai Nortye Announces First Patient Dosed in Intermittent Weekly Dosing Arm of Global Phase 1 Trial of Pan-RAS(ON) Inhibitor AN9025

Thu, 16 Jul 2026 07:00:00 -0400

First patient dosed in intermittent QW dosing arm with AN9025

Intermittent dosing offers a differentiated approach in the pan-RAS(ON) inhibitor space and may widen the therapeutic window based on preclinical data

Both QD and QW arms are now enrolling

Form 3 Adlai Nortye Ltd. For: Mar 18 Filed by: Sawhney Roger

Wed, 15 Jul 2026 10:33:00 -0400

si-local-file:///var/storage/secattach/20260715/26772491.html

Form 3 Adlai Nortye Ltd. For: Mar 18 Filed by: Sawhney Roger

Wed, 15 Jul 2026 10:33:00 -0400

si-local-file:///var/storage/secattach/20260715/26772491.html

Adlai Nortye adds two oncologists to scientific advisory board

Mon, 13 Jul 2026 07:00:52 -0400

Adlai Nortye Ltd. (NASDAQ: ANL), a clinical-stage biotechnology company, has appointed Dr. David S. Hong and Dr. Piro Lito to its Scientific Advisory Board, according to a company statement.

Dr. Hong serves as the Douglas E. Johnson Endowed Professor and Deputy Chair in the Department of Investigational Cancer Therapeutics at The University of Texas MD Anderson Cancer Center. He received his M.D. from Albert Einstein College of Medicine and completed his oncology fellowship at MD Anderson. He has authored hundreds of peer-reviewed publications and received awards including the Amgen Young Investigator Award and the Jesse H. Jones Award.

Dr. Lito holds the

Adlai Nortye Expands Scientific Advisory Board with Appointment of Two Leading Medical Oncologists

Mon, 13 Jul 2026 07:00:00 -0400

SINGAPORE and NORTH BRUNSWICK, N.J., July 13, 2026 (GLOBE NEWSWIRE) -- Adlai Nortye Ltd. (NASDAQ: ANL) (“Adlai Nortye” or the “Company”), a clinical-stage biotechnology company focused on the development of innovative cancer therapies, today announced the expansion of its Scientific Advisory Board (SAB) with the appointments of two leading medical oncologists, Dr. David S. Hong and Dr. Piro Lito.

“Adlai Nortye's pipeline is anchored by its RAS inhibitor programs, including AN9025, an oral pan-RAS(ON) inhibitor, and AN4035, a CEACAM5-targeting antibody drug conjugate (ADC) leveraging our RASiCA™ (RAS Inhibitor Conjugated Antibody) platform, alongside our tri-specific immuno-oncology candidate AN8025.

Adlai Nortye Expands Scientific Advisory Board with Appointment of Two Leading Medical Oncologists

Mon, 13 Jul 2026 07:00:00 -0400

Adlai Nortye Expands Scientific Advisory Board with Appointment of Two Leading Medical Oncologists

Mon, 13 Jul 2026 07:00:00 -0400